Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS)
Key facts
- Who runs it
- University Hospital Tuebingen
- Where
- Czechia, Germany, Italy, and Spain5 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 4 Jun 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Observational, 3 groups
- Record updated
- 6 April 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- SCA27B: genetic diagnosis of ≥250 uninterrupted GAA repeat expansions in FGF14
- SCA27B risk subject: asymptomatic first-degree relative of SCA27B participant with known or unknown carrier status
- Unrelated healthy controls: no signs or history of neurological or psychiatric disease AND
- Written informed consent AND
- Participants are willing and able to comply with study procedures
Who cannot take part
- Unrelated healthy controls: Missing informed consent, or concurrent neurological, orthopedic, or other diseases interfering with the motor assessments
- SCA27B: Missing informed consent
- SCA27B risk subjects: Missing informed consent
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This international, multi-center, multi-modal, and prospective observational cohort study aims to validate trial outcomes for capturing disease progression in Spinocerebellar Ataxia Type 27B (SCA27B), with combined multi-modal capture of clinical outcome assessments, digital-motor assessments, and molecular biomarkers.
The 3 groups in the trial
- SCA27B
Participants with genetically confirmed SCA27B (OMIM 620174), i.e. ≥250 uninterrupted GAA repeat expansions in FGF14, will be recruited. Target sample size for the SCA27B cohort is 200 participants.
- SCA27B risk subjects
First-degree relatives at risk for SCA27B, both with known and unknown carrier status, will be included to capture presymptomatic disease stages. Target sample size for the risk cohort is 50 participants
- Unrelated healthy controls
Unrelated healthy controls may undergo the same study procedures as the SCA27B cohort to determine age-related effects on the multimodal outcomes. Target sample size for the control cohort is 50.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06472557, who can take part
- Record updated
- 6 April 2026